Dicot Pharma Dicot Pharma
  • The Pharmaceutical Project
    • The drug candidate LIB-01
    • Sexual dysfunctions
    • The Market
    • Patent
    • Publications
    • Advisory expert group
  • About Dicot Pharma
    • Business idea, strategy & vision
    • Management
    • Board
    • Background
    • Contact
  • Media
    • Articles
    • Films
    • Podcasts
    • DICOTnews
  • Press
    • Press Releases
    • Press Images
  • Investor Relations
    • The share
    • Corporate governance
    • Reports and issues
    • Financial calendar and events
    • Analysis
    • Subscribe
  • Subscribe
  • The Pharmaceutical Project
    • The drug candidate LIB-01
    • Sexual dysfunctions
    • The Market
    • Patent
    • Publications
    • Advisory expert group
  • About Dicot Pharma
    • Business idea, strategy & vision
    • Management
    • Board
    • Background
    • Contact
  • Media
    • Articles
    • Films
    • Podcasts
    • DICOTnews
  • Press
    • Press Releases
    • Press Images
  • Investor Relations
    • The share
    • Corporate governance
    • Reports and issues
    • Financial calendar and events
    • Analysis
    • Subscribe
  • Subscribe
  • På svenska
På svenska
  • Home/
  • Investor Relations/
  • Reports and issues/
  • Previous issues

Previous issues

  • Financial reports
  • Rights issue 2026
  • TO 7 Warrants 2027
  • Previous issues

Rights issue 2026

Warrants TO6 2025

Rights issue 2024

Warrants TO5 2023

Warrants TO4 2023 (In Swedish)

Rights Issue 2023

Warrants TO3 2022 (In Swedish)

Rights issue 2021 (In Swedish)

Warrants TO2 2021 (In Swedish)

Rights issue 2020 (In Swedish)

Warrants TO1 2020 (In Swedish)

Dicot Pharma is developing a modern potency drug that will treat erectile dysfunction and premature ejaculation better than existing drugs.

Follow us on linkedIn  

Dicot Pharma AB
S:t Olofsgatan 11A
SE-753 21 Uppsala
SWEDEN

+46 72 502 10 10
[email protected]

© Copyright Dicot Pharma AB.
All rights reserved.

Change settings for cookies

Integrity policy and GDPR

Annual report 2025

Our website uses cookies to improve your experience and for targeted marketing.
You can configure what you want to accept and read more about the cookies we use here.

Accept all